Anti-abortion advocates are putting pressure on the Trump administration ahead of the 2026 midterm elections to curtail online access to the abortion pill mifepristone despite efforts from the new Food and Drug Administration chief to appease conservative voters.

After more than a year of tension between the Trump administration and anti-abortion Republicans, FDA officials confirmed last week that the agency is conducting a real-world safety study of mifepristone that takes into account data from online sales of the pill for at-home abortions.